

11<sup>th</sup> April, 2017

✓ The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

~~The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

**Sub.: Clarification / Information on news item**

With reference to your e-mail dated 10-Apr-17, referring to the news item appeared in The Economic Times on 08-Apr-17 titled “Torrent close to buying women healthcare portfolio of Swiss pharma major Novartis”, we hereby submit our response as follows:

The Company had executed certain agreements (“Agreement”) with Novartis AG, Basel, Switzerland and its Affiliate to acquire certain generic pharmaceutical products. The closure of the deal is subject to the approval of Competition Commission of India (“CCI”) and other applicable regulatory approvals. As the arrangement was not of material nature, the disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 (“Listing Regulations”) was not required.

As a responsible listed organisation, we do inform the Exchanges of all information which are required to be disclosed, on timely basis, in the terms of Listing Regulations and will continue to do so.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY